Fig. 2.

Summary of the Asia-Pacific multidisciplinary panel recommendations for the monitoring and management of T-DXd–related ILD/pneumonitis. The Managing ILD/pneumonitis section of this figure has been adapted from Fig. 3 of Swain SM et al 2021 [28]. ^aOther tests cited by guidelines and clinical trial protocol include blood culture and CBC, PFTs and pulse oximetry, arterial blood gases, PK analysis of blood sample (as clinically indicated and feasible) [28]. BAL bronchoalveolar lavage, CBC complete blood count, CMV cytomegalovirus, CT computed tomography, HRCT high-resolution computed tomography, ILD interstitial lung disease, IV intravenous, MDT multidisciplinary team, PFT pulmonary function test, PK pharmacokinetic, T-DXd trastuzumab deruxtecan